Formela Jean Francois Sells Shares of Korro Bio on NasdaqCM

Formela Jean Francois recently sold 3,962 shares of Korro Bio, Inc. (NasdaqCM: KRRO) in a planned transaction on June 22, 2026. The shares were sold at an average price of $13.95, totaling $55,269.90. This transaction is part of a series of insider activities at the company.

Insider Buying and Selling at Korro Bio, Inc.

In addition to the recent sale by Formela Jean Francois, who sold shares on multiple occasions in June 2026, other insiders also engaged in transactions. Jeffrey Cerio, General Counsel, sold 6,609 shares at $10.83 each on June 16, 2026, without a planned sale. Similarly, Oliver Dolan, Senior Vice President of Finance, and Loic Vincent, Chief Scientific Officer, each sold shares on the same day at the same price.

Other Institutional Activity in Korro Bio

Several institutional investors have been active in Korro Bio. LYNX1 Capital Management LP increased its holdings by 860,381 shares, ending with 1,538,296 shares valued at approximately $17.41 million, marking a 126.9% increase. NEA Management Company, LLC also grew its position by 207,100 shares to a total of 1,297,893 shares, worth about $14.69 million, a 19% increase. Balyasny Asset Management L.P. and Venrock Adviser, LLC both opened new positions with over a million shares each, valued at $11.77 million and $11.43 million, respectively.

Korro Bio, Inc. Stock Up 6.7%

Shares of Korro Bio traded near $13.77 on Thursday. The company has a market cap of approximately $200.5 million. Its forward P/E ratio is not meaningful as the company is not currently profitable, with an EPS of -11.64. The stock's beta is 2.096, indicating higher volatility compared to the market. Korro Bio's 52-week trading range has been between $5.20 and $55.89, with a 50-day moving average of $12.20 and a 200-day moving average of $17.71.

Analysts Set New Price Targets

Analysts have set optimistic price targets for Korro Bio. On May 19, 2026, HC Wainwright & Co. maintained a 'buy' rating with a $15 price target. Citigroup initiated coverage on May 18, 2026, with a 'buy' rating and a $21 target. Earlier, on March 13, 2026, Cantor Fitzgerald maintained a 'buy' rating with a $22 target, while Raymond James upgraded the stock to 'buy' with a $23 target. The consensus among ten analysts is a 'buy' rating, with an average target price of $20.

About Korro Bio

Korro Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing genetic medicines through RNA editing. Founded in 2018, the company aims to treat rare and common diseases using its proprietary RNA editing platform. Its lead candidate, KRRO-121, targets hyperammonemia. Korro Bio collaborates with Novo Nordisk to address cardiometabolic diseases. The company is led by CEO Dr. Ram Aiyar and employs 49 people.

Bottom Line

The recent insider sales by Formela Jean Francois are part of planned transactions and reflect ongoing insider activity at Korro Bio. Investors often track such activity for insights into company sentiment. Korro Bio's stock remains volatile, with a wide 52-week range, and analysts continue to see potential upside, as shown by recent price target updates. As always, insider transactions are disclosed after the fact and may not indicate future stock performance.